Literature DB >> 23563149

Overexpression of the truncated form of Livin reveals a complex interaction with caspase-3.

Gui-Hong Liu1, Chun Wang, Zhen-Yu Ding.   

Abstract

Disruption in apoptosis are involved in cancer development and progression. Livin-β, has been identified as a critical modulator for cell death in several tumor cell lines. It was demonstrated that a truncated fragment of Livin-β (tLivin) without its N-terminal 52 amino acids is produced in cells through protein cleavage. However, the biological consequence of the cleavage remains largely ignored. In the present study, we report that tLivin exerted a pro-apoptotic effect on cells. The subcellular localization of tLivin was mainly restricted to the cytoplasm. To explore the underlying mechanism, we observed an elevated caspase-3 activity which may account for the apoptosis. Furthermore, we observed that tLivin was further cleaved into a smaller fragment in cells. This second cleavage was possibly related to activated caspase-3. The resulted C-terminal fragment (livC) was an anti-apoptotic factor. Our study may help to deepen our understanding of the role of Livin in the regulation of cell death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23563149     DOI: 10.3892/ijo.2013.1883

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.

Authors:  Kuo Sun; Qi Liao; Zenggan Chen; Tongyi Chen; Jian Zhang
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

2.  tLivin displays flexibility by promoting alternative cell death mechanisms.

Authors:  Tamar Shiloach; Christian Berens; Christina Danke; Ortal Waiskopf; Riki Perlman; Dina Ben-Yehuda
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

3.  Prognostic value of Livin in surgical specimen and biopsy in patients with osteosarcoma.

Authors:  Jian Zhou; Nuo Xu; Yijun Kang; Wanchun Wang; Fei Chen
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.